AI Article Synopsis
- Rat fetuses at 20 days gestation were treated with the DNA methylation inhibitor 5-azacytidine, leading to a significant increase in the liver enzyme tyrosine aminotransferase.
- The enzyme level rose 70-fold compared to control levels, peaking 18 hours post-treatment, which is similar to levels seen in glucocorticoid-treated adult livers.
- Other compounds like cytidine, cytosine arabinoside, and 6-azacytidine had little to no effect on enzyme levels.
Article Abstract
Rat fetuses of 20 days gestational age were treated in utero with the inhibitor of DNA methylation, 5-azacytidine. The liver enzyme tyrosine aminotransferase, normally expressed at very low levels until several hours after birth, was increased by the drug in the fetal livers after a lag period of about 9 hours, reaching a level 70-fold above control levels 18 hours after treatment. The high levels attained after 5-azacytidine treatment are comparable to those of glucocorticoid-treated adult livers, and were not further increased by administration of hydrocortisone to dams carrying treated fetuses. Cytidine and two other analogs, cytosine arabinoside and 6-azacytidine, were essentially without effect.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0006-291x(83)91775-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Neurometabolic Function of the Dopamine-Aminotransferase System.
Metabolites
January 2025
Institute of Translational Biomedicine, Saint Petersburg State University, 199034 Saint Petersburg, Russia.
Background/objectives: The neurometabolic function is controlled by a complex multi-level physiological system that includes neurochemical, hormonal, immunological, sensory, and metabolic components. Functional disorders of monoamine systems are often detected in clinical practice together with metabolic dysfunctions. An important part of the mentioned pathological conditions are associated with disturbances in protein metabolism, some of the most important biomarkers which are aminotransferases and transcription factors that regulate and direct the most important metabolic reactions.
View Article and Find Full Text PDFPrognostic impact of primary versus secondary resistance to sorafenib in patients with HCC.
Ther Adv Med Oncol
January 2025
School of Clinical Medicine, Guizhou Medical University, Guiyang, China.
Background: Sorafenib is a first-line treatment option for patients with hepatocellular carcinoma (HCC). However, the impact of sorafenib resistance type on patient survival prediction and choice of second-line treatment regimen is unknown.
Objectives: This study aims to explore the factors predicting resistance in patients with HCC receiving sorafenib, the impact of resistance on survival, and the optimal second-line treatment regimen.
Third generation vs first generation EGFR-TKIs in the first line treatment for EGFR-mutated locally advanced or metastatic non-small cell lung cancer: a meta-analysis based on randomized controlled trials.
J Cancer
January 2025
Department of Respiratory and Critical Care Medicine, The Second People's Hospital of Jingdezhen, Jingdezhen, China.
The prevailing belief is that third-generation tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) (TGET) outperform first-generation EGFR-TKIs (FGET) in managing advanced-stage EGFR-mutated non-small cell lung cancer (NSCLC). However, this standpoint lacks substantiation in evidence-based medicine. Therefore, this meta-analysis was conducted to compare the efficacy and adverse effects (AEs) of these two categories.
View Article and Find Full Text PDFCharacterizing the ideal patient for treatment with inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: a systematic literature review.
Expert Rev Hematol
January 2025
Department of Medicine A, University of Münster, Münster, Germany.
Introduction: Inotuzumab ozogamicin (InO) is indicated for the treatment of adults with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL). This systematic literature review (CRD42022330496) assessed outcomes by baseline characteristics for patients with R/R ALL treated with InO to identify which patients may benefit most.
Methods: In adherence with PRISMA guidelines, searches were run in Embase and MEDLINE.
Osimertinib exacerbates immune checkpoint inhibitor-related severe adverse events by activating the IL-6/JAK/STAT3 pathway in macrophages.
Cancer Biol Med
December 2024
Department of Immunology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Tianjin 300060, China.
Objective: The combination of epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) leads to an increased incidence of severe immune-related adverse events (irAEs). However, the mechanisms underlying macrophages in irAEs have not been elucidated.
Methods: An osimertinib and ICI-induced irAE mouse model was constructed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!